Thursday, April 30, 2020

The fight for affordable insulin is more important than ever

We’re committed to keeping our community safe and healthy during COVID-19

Connected For Life

COVID-19 Reponse

Supporter, as COVID-19 becomes more pervasive, our efforts to keep the community safe are even more important—and for the more than 34 million Americans with diabetes, including nearly seven million who rely on insulin to live, our fight is personal.

Here’s why.

People living with diabetes face a greater risk of developing complications from COVID-19. Even scarier, this crisis is leaving many out of work and unable to afford their insulin and other medications and supplies.

And we can’t let that happen.

That’s why the American Diabetes Association® is advocating for a zero-dollar co-pay for insulin during this emergency. And we’re continuing to drive legislation to ensure that insulin is affordable and accessible for all. We’re also supporting legislation to guarantee uninterrupted health insurance coverage for those who have lost jobs.

That’s why we need your help. We need to ensure that all people living with diabetes can get the life-saving medications, supplies and insulin they need.

If you can, please consider making a donation to help us continue these advocacy efforts. For information about other medications or supplies, call 1-800-DIABETES (800-342-2383) or email askada@diabetes.org.

SUPPORT OUR MISSION

If you are struggling to pay for insulin or know someone who is, ADA has resources to help. Visit InsulinHelp.org.


There’s nothing we can’t do when we’re Connected for Life.
ADA Connected for Life logo

Facebook icon Twitter icon LinkedIn icon YouTube social icon Pintrist social icon Instagram icon

VIEW ONLINE  |  UPDATE YOUR PROFILE HERE

American Diabetes Association | 2451 Crystal Drive, Suite 900 | Arlington, VA 22202 | 1-800-DIABETES
Please add reply@diabetes.org to your address book to ensure you receive all future emails.
Click Here to Unsubscribe.

© 2020 American Diabetes Association. All rights reserved.

No comments:

Post a Comment